

Reference: FOI.ICB-2526/319

Subject: ICB Use of Tirzepatide (Mounjaro)

I can confirm that the ICB does hold some of the information requested; please see responses below:

QUESTION	RESPONSE								
1. Please provide the total cost to the ICB of tirzepatide (Mounjaro) since it became available across specialist weight management services and primary care settings on 23 June 2025. If possible, please break this down by month.	<p>From the date provided, this data assumes the question is asking for tirzepatide prescribing for weight loss in primary care under the NICE TA1026 funding variation.</p> <p>Between 23/6/25 – 13/1/26 there were 308 patients with general practice issued prescriptions for tirzepatide who had a code of “NHS medication pathway started”</p> <p>Spend per month for these patients using the pre-October 25 Mounjaro pricing below. Total for the period being £125,242.</p> <table> <tr> <td>After or on 23-Jun-2025 and before or on 22-Jul-2025</td><td>£5,589</td></tr> <tr> <td>After or on 23-Jul-2025 and before or on 22-Aug-2025</td><td>£10,050</td></tr> <tr> <td>After or on 23-Aug-2025 and before or on 22-Sep-2025</td><td>£13,512</td></tr> <tr> <td>After or on 23-Sep-2025 and before or on 22-Oct-2025</td><td>£17,948</td></tr> </table>	After or on 23-Jun-2025 and before or on 22-Jul-2025	£5,589	After or on 23-Jul-2025 and before or on 22-Aug-2025	£10,050	After or on 23-Aug-2025 and before or on 22-Sep-2025	£13,512	After or on 23-Sep-2025 and before or on 22-Oct-2025	£17,948
After or on 23-Jun-2025 and before or on 22-Jul-2025	£5,589								
After or on 23-Jul-2025 and before or on 22-Aug-2025	£10,050								
After or on 23-Aug-2025 and before or on 22-Sep-2025	£13,512								
After or on 23-Sep-2025 and before or on 22-Oct-2025	£17,948								

	After or on 23-Oct-2025 and before or on 22-Nov-2025	£25,763
	After or on 23-Nov-2025 and before or on 22-Dec-2025	£30,870
	After or on 23-Dec-2025 and before or on 22-Jan-2026	£21,510
<p>2. How many patients have been prescribed tirzepatide since the 23 June 2025? Please can you provide an overall total and monthly totals if possible (e.g., 23 June–23 July, 23 July–23 August, etc.)</p>	Date	Number of patients prescribed tirzepatide by general practice for weight loss
	After or on 23-Jun-2025 and before or on 22-Jul-2025	41
	After or on 23-Jul-2025 and before or on 22-Aug-2025	85
	After or on 23-Aug-2025 and before or 22-Sep-2025	116
	After or 23-Sep-2025 and before or 22-Oct-2025	163
	After or 23-Oct-2025 and before or 22-Nov-2025	205
	After or 23-Nov-2025 and before or 22-Dec-2025	225
	After or 23-Dec-2025 and before or 07-Jan-2026	90
	Total number of patients prescribed tirzepatide for weight loss by general practice in the period 23/6/25 – 7/1/26 is 268 patients	

<p>3. Does your ICB have any thresholds for treatment that differ from the national thresholds – if so, what are your local thresholds?</p>	<p>No, we are following the NHS England Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity NHS England » Interim commissioning guidance: implementation of the NICE technology appraisal TA1026 and the NICE funding variation for tirzepatide (Mounjaro®) for the management of obesity</p>
<p>4. How many patients who met the national eligibility threshold for tirzepatide have been declined treatment by the ICB or by services commissioned by the ICB?</p>	<p>The ICB does not hold this information; this information will be held at practice level.</p>
<p>5. How many patients are currently on a waiting list for tirzepatide treatment?</p>	<p>The ICB does not hold this information; this information will be held at practice level.</p>

The information provided in this response is accurate as of 14 January 2026 and has been approved for release by Dr Geeta Iyer, Deputy Chief Medical Officer for NHS Bristol, North Somerset and South Gloucestershire ICB.